Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Braz. J. Pharm. Sci. (Online) ; 58: e19500, 2022. tab, graf
Article in English | LILACS | ID: biblio-1383990

ABSTRACT

Abstract The pursuit of quality of life, which has become marked in recent years, has translated into important population health benefits. This study assessed the quality of life of patients with type 2 diabetes (T2DM) who received pharmaceutical care, and their satisfaction with the service provided in community pharmacies. This single blind, randomized controlled clinical trial included 100 patients. The intervention group (N=47) received pharmaceutical care by a clinical pharmacist and the control group (N=42) received standard care. The Quality of Life Diabetes Questionnaire (DQOL) was used to measure all participants´ quality of life at study enrollment and six months later. Satisfaction of the participants in the intervention group was measured using a validated 14-items questionnaire. At the end of the study, participants in the intervention group had a statistically significant improvement in DQOL scores ( -0.62 x 1.57, p < 0.001) and were highly satisfied with the intervention (96% excellent satisfaction scores). Pharmaceutical care practice was associated with high satisfaction and increased quality of life scores in T2DM patients. These results underscore the important role of pharmacists to improve the health of diabetic patients.


Subject(s)
Humans , Male , Female , Adult , Patients/classification , Quality of Life , Randomized Controlled Trial , Practice Patterns, Pharmacists'/ethics , Pharmaceutical Services , Patient Satisfaction , Diabetes Mellitus, Type 2/pathology
2.
Rev. ciênc. farm. básica apl ; 41: [13], 01/01/2020. tab, ilus
Article in English | LILACS | ID: biblio-1128572

ABSTRACT

The therapeutic drug monitoring (TDM) is an important strategy for the effectiveness and safety of long-term pharmacotherapy, such as the use of phenobarbital as an anticonvulsant drug in epilepsy. In this sense, HLPC has been presented as a technique for the measurement of phenobarbital in serum. However, the ideal conditions for carrying out the method must be established for each laboratory reality. An analytical method using HPLC was developed and validated in order to identify and quantify Phenobarbital in blood. The chromatographic conditions were C-18 column (Shimpack XR-ODS 50L x 3.0), acetonitrile-water mobile phase (30:70, v v-1), 0.2 mL min-1 flow and reading wavelength of 210 nm. Linearity was established in the range of 2.5 to 80 µg mL-1, the linear correlation coefficient was 0.9981. The average of the coefficient of variation of the precision was 5.30%. The relative standard error of the accuracy was -2.17% and of the recovery coefficient was 97.83%. In all eleven patients, phenobarbital concentrations were below the therapeutic range. The tested method was selective, linear, precise, accurate and showed good recovery.(AU)


Subject(s)
Humans , Male , Female , Phenobarbital/blood , Drug Monitoring/methods , Anticonvulsants/pharmacokinetics , Phenobarbital/adverse effects , Chromatography, High Pressure Liquid/methods , Drug Combinations , Validation Studies as Topic
SELECTION OF CITATIONS
SEARCH DETAIL